Cargando…

Magnetic Resonance Imaging-Based Radiomic Profiles Predict Patient Prognosis in Newly Diagnosed Glioblastoma Before Therapy

Magnetic resonance imaging (MRI) is used to diagnose and monitor brain tumors. Extracting additional information from medical imaging and relating it to a clinical variable of interest is broadly defined as radiomics. Here, multiparametric MRI radiomic profiles (RPs) of de novo glioblastoma (GBM) br...

Descripción completa

Detalles Bibliográficos
Autores principales:	McGarry, Sean D., Hurrell, Sarah L., Kaczmarowski, Amy L., Cochran, Elizabeth J., Connelly, Jennifer, Rand, Scott D., Schmainda, Kathleen M., LaViolette, Peter S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Grapho Publications, LLC 2016
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5074084/ https://www.ncbi.nlm.nih.gov/pubmed/27774518 http://dx.doi.org/10.18383/j.tom.2016.00250

Ejemplares similares

2555 Predictive cytological topography (PiCT): A radiopathomics approach to mapping prostate cancer
por: McGarry, Sean D., et al.
Publicado: (2018)

Radio-pathomic Maps of Epithelium and Lumen Density Predict the Location of High-Grade Prostate Cancer
por: McGarry, Sean D., et al.
Publicado: (2018)

Optimized b-value selection for the discrimination of prostate cancer grades, including the cribriform pattern, using diffusion weighted imaging
por: Hurrell, Sarah L., et al.
Publicado: (2017)

Radiomic Features of Multiparametric MRI Present Stable Associations With Analogous Histological Features in Patients With Brain Cancer
por: Bobholz, Samuel A., et al.
Publicado: (2020)

Radiomics and MGMT promoter methylation for prognostication of newly diagnosed glioblastoma
por: Sasaki, Takahiro, et al.
Publicado: (2019)

Gleason Probability Maps: A Radiomics Tool for Mapping Prostate Cancer Likelihood in MRI Space
por: McGarry, Sean D., et al.
Publicado: (2019)

Radiomic Deformation and Textural Heterogeneity (R-DepTH) Descriptor to Characterize Tumor Field Effect: Application to Survival Prediction in Glioblastoma
por: Ismail, Marwa, et al.
Publicado: (2022)

Case report: Fractional brain tumor burden magnetic resonance mapping to assess response to pulsed low-dose-rate radiotherapy in newly-diagnosed glioblastoma
por: Amidon, Ryan F., et al.
Publicado: (2022)

Avelumab in newly diagnosed glioblastoma
por: Jacques, Francois H, et al.
Publicado: (2021)

Integration of Radiomic and Multi-omic Analyses Predicts Survival of Newly Diagnosed IDH1 Wild-Type Glioblastoma
por: Chaddad, Ahmad, et al.
Publicado: (2019)

Prognostic Value of TSPO PET Before Radiotherapy in Newly Diagnosed IDH–Wild-Type Glioblastoma
por: Albert, Nathalie L., et al.
Publicado: (2023)

Acid ceramidase confers radioresistance to glioblastoma cells
por: Doan, Ninh B., et al.
Publicado: (2017)

Advances in the treatment of newly diagnosed glioblastoma
por: Theeler, Brett J., et al.
Publicado: (2015)

A Review of Newly Diagnosed Glioblastoma
por: Oronsky, Bryan, et al.
Publicado: (2021)

Newly Diagnosed Glioblastoma in Elderly Patients
por: Yuen, Carlen A., et al.
Publicado: (2022)

ACRIN 6684: Multicenter, phase II assessment of tumor hypoxia in newly diagnosed glioblastoma using magnetic resonance spectroscopy
por: Ratai, Eva-Maria, et al.
Publicado: (2018)

TIPS-03 A PHASE 1 STUDY OF GALLIUM MALTOLATE (GAM) IN PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM)
por: Connelly, Jennifer, et al.
Publicado: (2023)

Correction: Newly Diagnosed Glioblastoma in Elderly Patients
por: Yuen, Carlen A., et al.
Publicado: (2022)

Interstitial photodynamic therapy for newly diagnosed glioblastoma
por: Quach, Stefanie, et al.
Publicado: (2023)

Acid ceramidase and its inhibitors: a de novo drug target and a new class of drugs for killing glioblastoma cancer stem cells with high efficiency
por: Doan, Ninh B., et al.
Publicado: (2017)

Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome
por: Weller, Michael, et al.
Publicado: (2016)

Effect of Cadherin-11 Expression on the Prognosis of a Newly Diagnosed Primary Glioblastoma
por: Seo, Hyunwoo, et al.
Publicado: (2021)

Survival with dacarbazine and fotemustine in newly diagnosed glioblastoma multiforme
por: Fazeny-Dörner, B, et al.
Publicado: (2003)

Subclassification of Newly Diagnosed Glioblastomas through an Immunohistochemical Approach
por: Conroy, Siobhan, et al.
Publicado: (2014)

Radiotherapy for Newly Diagnosed Glioblastoma in the Elderly: What Is the Standard?
por: Wee, Chan Woo
Publicado: (2022)

The timing of cranial radiation in elderly patients with newly diagnosed glioblastoma multiforme
por: Lai, Rose, et al.
Publicado: (2010)

Are we providing best-available care to newly diagnosed glioblastoma patients? Systematic review of phase III trials in newly diagnosed glioblastoma 2005–2022
por: Oster, Christoph, et al.
Publicado: (2023)

Bench to bedside radiosensitizer development strategy for newly diagnosed glioblastoma
por: Degorre, Charlotte, et al.
Publicado: (2021)

Radiomics in the diagnosis of glioblastoma
por: Kwiatkowska-Miernik, Agnieszka, et al.
Publicado: (2023)

The prognosis for patients with newly diagnosed glioblastoma receiving bevacizumab combination therapy: a meta-analysis
por: Liao, Ke-Li, et al.
Publicado: (2018)

The prognostic value of FET PET at radiotherapy planning in newly diagnosed glioblastoma
por: Poulsen, Sidsel Højklint, et al.
Publicado: (2016)

Standard 6-week chemoradiation for elderly patients with newly diagnosed glioblastoma
por: Vaugier, Loïg, et al.
Publicado: (2021)

Early Therapeutic Interventions for Newly Diagnosed Glioblastoma: Rationale and Review of the Literature
por: Waqar, Mueez, et al.
Publicado: (2022)

Survival impact of delaying postoperative chemoradiotherapy in newly-diagnosed glioblastoma patients
por: Zhang, Maochen, et al.
Publicado: (2020)

Feasibility of fractionated gamma knife radiosurgery in the management of newly diagnosed Glioblastoma
por: Gallitto, Matthew, et al.
Publicado: (2022)

Timing of bevacizumab administration after biopsy for unresectable newly diagnosed glioblastoma
por: Matsuda, Masahide, et al.
Publicado: (2022)

Clinical Outcomes of Moderately Hypofractionated Concurrent Chemoradiotherapy for Newly Diagnosed Glioblastoma
por: Kim, Nalee, et al.
Publicado: (2023)

Antisecretory factor is safe to use as add-on treatment in newly diagnosed glioblastoma
por: Ehinger, Erik, et al.
Publicado: (2023)

Magnetic Resonance Imaging Mapping of Brain Tumor Burden: Clinical Implications for Neurosurgical Management: Case Report
por: Connelly, Jennifer M, et al.
Publicado: (2021)

Prospective biomarker study in newly diagnosed glioblastoma: Cyto-C clinical trial
por: Griguer, Corinne E, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9jdvdfr1p3ce0elr0ivrvcrft3